Medgenics Announces Pricing of Secondary Offering
Medgenics saw its shares drop on Tuesday after the company announced the pricing of its secondary offering.
All Work
Chris Lange
Planet Fitness Gears Up for Secondary Offering
Selling stockholders are offering up 10 million Planet Fitness shares. At Monday’s closing price, the entire offering is valued up to more than $224 million.
With Acquisitions, Will Impax Become the Next Great Generic Drug Seller?
Impax Laboratories plans to take on a substantial portfolio of generic drugs in a transaction that will be immediately accretive and allow for accelerating growth in the years to come.
Are Shareholders Getting Enough in the AS&E Acquisition?
American Science & Engineering has entered into a definitive agreement to be acquired by OSI Systems in an all-cash transaction.
Global Blood Therapeutics Rises After Pricing Secondary Offering
Global Blood Therapeutics shares saw a handy gain in the premarket on Tuesday, despite the company pricing its secondary offering below its previous price level.
CarMax Earnings Fail to Impress
CarMax reported disappointing fiscal first-quarter financial results before the markets opened on Tuesday.
What to Expect From CarMax Earnings
CarMax Inc. (NYSE: KMX) is set to report fiscal first-quarter financial results before the markets open Tuesday. The consensus estimates from Thomson Reuters are calling for $0.92 in earnings per share (EPS) on $4.20…
What to Expect From FedEx Earnings
FedEx is scheduled to report its fiscal fourth-quarter financial results after the markets close on Tuesday.
Gilead Sciences Bounces on Preliminary Results
Shares of Gilead Sciences Inc. (NASDAQ: GILD) saw make a handy gain just off of their 52-week low following the release of preliminary data from its HIV treatment. After the stock dropped about 17.5% so far…
Selecta Biosciences Closes in on IPO
Selecta Biosciences intends to price more than 4 million shares in the range of $14 to $16 per share for an initial public offering valued up to more than $78 million.
Syros Pharmaceuticals Announces Potential Pricing for IPO
Syros Pharmaceuticals expects to price 4 million shares in the range of $14 to $16 per share in an intial public offering valued up to more than $73 million.
How Inovio Pharma Is Joining the Fight Against the Zika Virus
Inovio Pharmaceuticals has announced that it received approval to initiate a Phase 1 human trial to evaluate its Zika DNA vaccine (GLS-5700) to prevent infection from the Zika virus.
Could This Be a Turning Point for Fate Therapeutics?
Shares of Fate Therapeutics saw a healthy gain early on Monday following a key U.S. Food and Drug Administration (FDA) approval.
Top 5 Earnings to Look for in the Coming Week
24/7 Wall St. has put together a look at FedEx, BlackBerry and some of the other companies that are reporting their earnings in the coming week.
6 Companies That Destroyed Shareholders Last Week
Whole Foods, Synchrony Financial and others led the charge in last week's market pullback and absolutely crushed shareholders.
Why Analysts Became More Bullish on Finisar
After Finisar reported its fiscal fourth-quarter financial results, a few analysts poured into the stock, generally raising their price targets.
How Analysts View Oracle After Earnings
Analysts piled into Oracle after it had a positive report, although their views were somewhat mixed.
Smith & Wesson Blows the Bottom Line out of the Water
Smith & Wesson reported better-than-expected fiscal fourth-quarter financial results after the markets closed on Thursday.
Comtech Sets Price for Secondary Offering
Comtech Telecommunications shares dropped handily in Friday’s session after the company announced the pricing of its secondary offering.
Lumber Liquidators Stops Sale of Remaining China-Made Laminate Flooring
Lumber Liquidators has agreed not to resume the sale of its inventory of Chinese-made laminate wood flooring.